Swertia

Swertia: A Comprehensive Reference

1. Identity, Taxonomy, and Botanical Description

Genus and Family. Swertia L. is a large genus of annual and perennial herbs in the family Gentianaceae (the gentian family). Swertia is a diverse genus comprising roughly 170 species distributed throughout the world, but is most diverse in temperate and subtropical regions and in montane tropics. The genus is widely distributed in Asia, Africa, and North America, with only a few species found in Europe. Of the 170 species, 79 are found in China, and these are most abundant in the Qinghai–Tibetan Plateau. Members of the genus are sometimes referred to as felworts.

Most Medically Important Species. Among the many species in the genus, Swertia chirayita (Roxb. ex Fleming) H. Karst. — known variously as chirayita, chirata, chiretta, or Indian gentian — is by far the most extensively studied and commercially significant. Swertia chirayita (Gentianaceae), a popular medicinal herb indigenous to the temperate Himalayas, is used in traditional medicine to treat numerous ailments such as liver disorders, malaria, and diabetes and is reported to have a wide spectrum of pharmacological properties. Additional medically important species include S. japonica, S. mussotii, S. angustifolia, S. paniculata, S. bimaculata, S. mileensis, and S. perennis, each with their own regional and pharmacological profiles.

Botanical Description of S. chirayita. S. chirayita (common name: "Chiretta") is a critically endangered medicinal herb that grows at high altitudes in the sub-temperate regions of the Himalayas, between 1,200 and 2,100 m altitudes from Kashmir to Bhutan, on the slopes of moist shady places. The plant is an erect annual or biennial herb with an orange-brown stem, opposite ovate leaves, and small four-petaled flowers. Capsules are egg-shaped and 2-valved with a transparent yellowish pericarp; seeds are numerous, very small, and dark brownish in color.

Taxonomic Note on Chinese Swertia. In China, many Swertia species are used as traditional Tibetan medicines, known as "Zangyinchen" or "Dida." Approximately 133 species (including varieties) in 17 genera of Gentianeae are used in traditional Chinese medicine, among which Gentiana and Swertia constitute the largest number of species with 60 and 35 species, respectively, accounting for 71% of the species.

Nomenclature and Synonyms. The species S. chirayita is known in Sanskrit as Kirata-tikta ("bitter herb of the Kiratas"), and in common usage as chirayata, chirata, chirayita, or Indian balmony. Its medicinal usage is well-documented in the Indian Pharmaceutical Codex, the British, and the American Pharmacopeias and in different traditional medicine systems such as Ayurveda, Unani, Siddha, and other conventional medical systems.

Common Preparations and Dosage Forms. The entire above-ground plant — stem, leaves, and flowers — is the part most commonly used medicinally, though roots are also utilized. Preparations include crude dried plant material, aqueous and methanolic extracts, decoctions (water-boiled preparations), powders, tinctures, and standardized commercial extracts. Herbal formulations such as Ayush-64, Diabecon, Mensturyl syrup, and Melicon V ointment contain S. chirayita extract in different concentrations for its antipyretic, hypoglycaemic, antifungal, and antibacterial properties. The plant is also used in the preparation of branded herbal drugs including Diabegon, D-400, Chirayita tablet, GlucoBuster, DBCare, Himoliv, and Melicon V; it is one of the ingredients in Ayurvedic formulations such as Kabdeen (for treating viral hepatitis) and Sudarshan churna.

2. Traditional and Historical Use

2.1 Ayurveda and South Asian Traditions

According to the Charaka Samhita Sutra, the earliest use of this plant is for Jvaraghna (antipyretic) and stanyasodhana (purification of breast milk). The earliest recorded use is in the Charaka Samhita Sutra (3rd to 2nd century BCE), where the species is recommended for reducing fever (jvaraghna). This makes chirayita one of the most ancient continuously documented botanical medicines of the Indian subcontinent.

The plant has been traditionally used to cure various ailments such as fever, vomiting, jaundice, digestive disorders, heart diseases, diabetes, malaria, scorpion bite, and skin diseases. The wide range of medicinal uses includes the treatment of chronic fever, malaria, anemia, bronchial asthma, hepatotoxic disorders, liver disorders, hepatitis, gastritis, constipation, dyspepsia, skin diseases, worms, epilepsy, ulcers, scanty urine, hypertension, melancholia, and certain types of mental disorders, as well as stimulation of bile secretion and blood purification.

Traditionally, decoctions of this species are used for anthelmintic, hepatoprotective, hypoglycemic, antimalarial, antifungal, antibacterial, cardiostimulant, antifatigue, anti-inflammatory, antiaging, antidiarrheal applications, as a protectant of the heart, and also to help in lowering blood pressure and blood sugar.

2.2 Traditional Chinese Medicine and Tibetan Medicine

Swertia species have been used in Indian traditional medical systems, the traditional Chinese system, and traditional Tibetan folk medicine for treating various ailments. In China, they have also been used as medicinal herbs for treating hepatitis, cholecystitis, pneumonia, osteomyelitis, dysentery, and scabies.

Approximately 83 species from Gentianeae were used in Tibetan medicine, among which Gentiana and Swertia constituted the largest number of species, with 42 and 24 species respectively. In Tibetan medicine, Swertia species are collectively known as "Zangyinchen" or "Dida" and have been used extensively to treat liver and bile duct conditions, infectious fevers, and inflammatory disorders.

2.3 Japanese Traditional Medicine

Swertia japonica has a long history of use in Japan as a bitter stomachic — that is, a bitter digestive tonic. The anticholinergic action of Swertia japonica, used in Japan as a bitter stomachic, was examined using in vivo experiments in rats in order to substantiate the presence or absence of antispasmodic properties. This species, also known as Japanese swertia or senburi in Japanese, was prepared as a decoction and taken for stomach complaints, poor appetite, and gastrointestinal discomfort.

2.4 Unani Medicine

In Unani medicine — the Greco-Arabic medical tradition practiced across South Asia and the Middle East — chirayita is known by the Arabic/Persian name Chiraita. Swertia plants have been considered to be medicinal plants useful for the treatment of various ailments for thousands of years, especially in Asian countries. In the Unani system, it is classified as a bitter tonic and antipyretic, used in formulations targeting liver diseases and fevers, and described in the Unani Pharmacopeia of India.

3. Key Constituents and Active Compounds

Approximately 419 metabolites and 40 bioactive compounds have been reported from 30 Swertia species, including xanthones, flavonoids, seco-iridoids, iridoids, triterpenoids, alkaloids, volatiles, and other secondary metabolites. For S. chirayita specifically, approximately 123 specialized metabolites including xanthones, seco-iridoids, terpenoids, alkaloids, and flavonoids have been isolated and characterized.

3.1 Seco-Iridoid Glycosides

These are the most pharmacologically investigated class of compounds in Swertia.

• Amarogentin — Amarogentin, a bitter secoiridoid glycoside present in Swertia chirata, is an activator of the human bitter taste receptor. The bitterness in S. chirayita is primarily due to the presence of two secoiridoid glycosides: amarogentin and amaroswerin. Amarogentin is one of the most intensely bitter natural substances known and is considered a chemotaxonomic marker of the genus.
• Swertiamarin — Swertiamarin, a seco-iridoid glycoside, is mainly found in Enicostemma littorale Blume and exhibits therapeutic activities for various diseases. It is also a major constituent of several Swertia species. Based on reported evidence, swertiamarin meets all five of Lipinski's rules for drug-like properties.
• Amaroswerin — another secoiridoid found alongside amarogentin that contributes to the characteristic bitterness of the plant.
• Sweroside and Gentiopicrin (Gentiopicroside) — additional secoiridoids reported from multiple species, including S. pubescens.

3.2 Xanthones

The medicinal plants of Swertia L. mainly contain chemical components including triterpenes, xanthones, and iridoids. These compounds exert pharmacological effects including ameliorating diseases related to the liver and gallbladder. Key xanthones identified include:

• Mangiferin — a C-glucosyl xanthone present in many Swertia species and one of the most extensively studied individual compounds from the genus. It is named for its parallel presence in Mangifera indica (mango).
• Swerchirin — a xanthone found in the hexane fraction of S. chirayita; swerchirin, one of the most important xanthones present in the plant extract, was identified to make maximum influence on insulin release and maximum reduction of blood sugar level up to 41% in experimental models.
• Bellidifolin and Desmethylbellidifolin — xanthones characterized in S. mussotii and several other species.
• Decussatin and Norswertianin — additional xanthone derivatives contributing to the chemotaxonomic profile of the genus. The first xanthone O-glycoside, norswertianin-1-O-glucosyl-3-O-glucoside, was isolated from S. perennis.

3.3 Alkaloids

The whole plant contains various important secondary metabolites and phytoconstituents, which include alkaloids (gentiamine, gentiocrucine, enicoflavine). Gentianine, a pyridine alkaloid metabolically derived from swertiamarin by intestinal microflora, is also noted as a pharmacologically active metabolite of swertiamarin.

3.4 Triterpenoids

Triterpenoids found in S. chirayita include episwertenol, oleanolic acid, swertanone, swertenol, and ursolic acid. Oleanolic acid has also been identified in S. pubescens.

3.5 Flavonoids and Other Phenolics

Phytoconstituents identified in S. chirayita using HPLC analysis include quercetin, gallic acid, swertiamarin, ferulic acid, rutin, and amarogentin. Flavonoids such as isoorientin have also been identified in other species such as S. pubescens.

3.6 Other Identified Constituents

Mangiferin, swerchirin, amaroswerin, gentianine, bellidifolin, swertiamarin, and amarogentin are the major phytochemical constituents in S. chirayita. Different fatty acids such as stearic acid, oleic acid, and palmitic acid have also been reported from this plant.

4. Mechanisms of Action

4.1 Swertiamarin: Molecular Targets

Swertiamarin is a potent compound with diverse pharmacological activities, including hepatoprotective, analgesic, anti-inflammatory, antiarthritis, antidiabetic, antioxidant, neuroprotective, and gastroprotective activities. The anticancer activity of swertiamarin against different cancer cell lines has also been recently reported. The underlying mechanisms of all these pharmacological effects are diverse and seem to involve the regulation of different molecular targets, including growth factors, inflammatory cytokines, protein kinases, apoptosis-related proteins, receptors, and enzymes.

Analysis demonstrates that swertiamarin exerts remarkable therapeutic potential across multiple pathological conditions through coordinated modulation of key signaling cascades, including Nrf2/HO-1, NF-κB, MAPK, PI3K/Akt, and PPAR pathways. SW can target Nrf2/HO-1 to inhibit oxidative stress to exert hepatoprotective, anti-diabetic, and neuroprotective effects.

Swertiamarin has been highlighted for anti-epilepsy, hypolipidemic, anti-osteoclastogenic, anti-nociceptive, anti-atherosclerotic, anti-hyperplasia, hepatoprotective, and antidepressant effects. Moreover, swertiamarin was also reported to relieve pain, cure gastrointestinal motility, and prevent cardiac and metabolic diseases.

The mechanism by which swertiamarin reduces diabetes includes a reduction in blood glucose, HbA1c, total cholesterol, triglycerides, and LDL levels.

A key metabolic transformation is also noted: swertiamarin undergoes metabolic conversion to gentianine by intestinal microflora. This conversion may account for some of the CNS-related activities attributed to Swertia preparations. Pharmacokinetic studies reveal that swertiamarin exhibits rapid absorption but demonstrates low oral bioavailability due to the first-pass effect.

4.2 Amarogentin: Bitter Receptor Activation and Anticancer Mechanisms

Pharmacologically, amarogentin has antibacterial, antihepatitis, anticholinergic, and chemopreventive activities; moreover, amarogentin has been proven for its anti-leishmanial activity. Other studies also suggested that amarogentin acts on liver carcinogenesis, skin carcinogenesis, and reduced tumour progression.

A comparable in silico analysis showed that amarogentin can inhibit two potential molecular targets for cancer — nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2). The least binding energies of amarogentin with NF-κB and COX-2 are -7.173 and -7.649, respectively. The molecular simulation of amarogentin suggests it has better binding affinities with both cancer targets than the reference compound serpentine.

4.3 Swerchirin: Insulin Secretagogue Activity

In animal models, swerchirin was identified to make maximum influence on insulin release and maximum reduction of blood sugar level up to 41%. This effect has been attributed to stimulation of pancreatic beta-cell activity, though mechanisms at the receptor level have not been fully elucidated in human studies.

4.4 Xanthones (Including Mangiferin): Antioxidant and Anti-inflammatory Roles

Mangiferin and related xanthones from Swertia are well established as polyphenolic antioxidants. Their anti-inflammatory activity is linked to inhibition of NF-κB signaling, suppression of COX-2, and reduction of pro-inflammatory cytokines such as TNF-α and IL-6 — mechanisms established in cell culture and animal studies but not yet fully validated in human clinical trials.

5. Scientific Evidence by Area of Use

5.1 Liver Protection (Hepatoprotective Activity)

Hepatoprotection is one of the most studied and traditionally best-supported areas for Swertia. The extract and isolated compounds exhibited a wide spectrum of pharmacological effects such as anti-inflammatory, antioxidant, antitumor, hepatoprotective, antiviral, antimalarial, and antibacterial, offering scientific evidence for traditional claims of this medicinal plant.

Preclinical (animal) evidence. The methanol extract of Swertia chirata was evaluated for antihepatotoxic activity against carbon tetrachloride-induced liver toxicity in experimental rats. The extract was found to be active, and on fractionation into butanol-soluble and chloroform-soluble fractions, the activity was traced and found most profound in the chloroform-soluble fraction. Extracts of Swertia chirata were evaluated for antihepatotoxic activity using paracetamol and galactosamine models. The methanol extract of the whole plant was found active at a dose of 100 mg/kg i.p.; on fractionation, the chloroform-soluble fraction was most active at a dose level of 25 mg/kg i.p., with overall protection of 81% and 78% against paracetamol and galactosamine, respectively.

A study examined the ability of plant extracts to offer protection against acute hepatotoxicity induced by paracetamol (150 mg/kg) in Swiss albino mice. Oral administration of S. chirayita extract (100–200 mg/kg) offered significant dose-dependent protection against paracetamol-induced hepatotoxicity as assessed in terms of biochemical and histopathological parameters. Administration of the plant extracts after paracetamol insult restored the levels of these parameters to control (untreated) levels.

Swertia chirata (Gentianaceae), one of the oldest medicinal herbs of India, is a source of the Indian Ayurvedic drug "chirata" used for the treatment of liver disorders and malarial fevers. In one study, eight species of Swertia were collected; each of the dry whole plants was extracted into methanol, the aqueous extract of which was sequentially extracted into hexane, chloroform, and butanol. The extracts were screened for their anti-hepatotoxic activity against carbon tetrachloride (CCl4) and paracetamol toxicity in primary monolayer cultures of rat hepatocytes.

Limitations. The hepatoprotective evidence base is almost entirely preclinical (animal and cell-culture models). Despite its extensive historical usage in traditional herbal medicine, there is currently a scarcity of scientific evidence on the safety of S. chirayita. No controlled human clinical trials specifically investigating hepatoprotection in humans have been published and confirmed in the peer-reviewed literature as of the date of this article.

5.2 Antidiabetic and Hypoglycemic Activity

Preclinical evidence. Reported pharmacological studies have demonstrated Swertia chirayita to exhibit anti-diabetic activity among other pharmacological properties. In one study, the hexane extract of the whole plant was evaluated for blood sugar-lowering abilities in male albino rats; swerchirin, one of the most important xanthones present in the plant extract, was identified to make maximum influence on insulin release and maximum reduction of blood sugar level up to 41%.

Some medicinal plants, including Swertia longifolia and Swertia chirayita, which contain swertiamarin as one of the major ingredients, have been reported to have antidiabetic properties.

Limitations. Numerous chemical constituents with promising pharmacological properties have been identified from plant extracts but still have not been well characterized, specifically against human application. The antidiabetic evidence base remains predominantly animal-based. Large, well-controlled human clinical trials are lacking.

5.3 Antimalarial Activity

The whole plant is widely used by local people for the treatment of hepatitis, inflammation, and digestive diseases. Antimalarial use is well-established in traditional and ethnobotanical literature. S. chirayita has been assessed in preclinical models for activity against Plasmodium species. This is part of the broader set of bioactivities identified in the genus: the bioactivities of Swertia plants include anticarcinogenic, hepatoprotective, anti-oxidant, hypoglycemic, anthelmintic, antibacterial, antifungal, anti-diabetic, gut and airways modulatory, metabolizing isozymes inhibitory, neuroprotective, HIV-I reverse transcriptases inhibitory, anticholinergic, and CNS-depressant activities.

Limitations. Clinical evidence for antimalarial efficacy in humans is very limited. Studies remain at the preclinical stage. The plant should not be considered a replacement for established antimalarial agents.

5.4 Anti-inflammatory and Antioxidant Activity

Anti-inflammatory and antioxidant effects have been demonstrated extensively in vitro and in animal models. These are attributed largely to the xanthone and flavonoid fractions. Pharmacological studies have demonstrated that swertiamarin possesses a wide range of pharmacological activities, including antioxidant, anti-inflammatory, anti-tumor, anti-diabetic, and neuroprotective activities. The modulation of Nrf2/HO-1 and NF-κB signaling cascades provides a molecular basis for these effects, but human clinical validation is lacking.

5.5 Anticancer Activity

Amarogentin is reported to be anti-diabetic, anticancerous, and antileishmanial. The anticancer activity of swertiamarin against different cancer cell lines has been recently reported. These findings are from in vitro (cell line) studies and in silico (computational docking) analyses. No human clinical trials on Swertia extracts or isolated compounds for cancer treatment have been reported in peer-reviewed literature.

5.6 Gastrointestinal and Bitter Tonic Activity

The use of Swertia japonica and S. chirayita as bitter digestive tonics is supported by both traditional records and some preclinical data. Effects of Swertia japonica extract and its main compound swertiamarin on gastric emptying and gastrointestinal motility were studied in mice. Amarogentin's activity as a human bitter taste receptor agonist provides a mechanistic basis for the observed stimulation of digestive secretions and appetite that underlies the traditional role of these plants as bitter stomachics.

5.7 Antileishmanial Activity

Pharmacologically, amarogentin has antibacterial, antihepatitis, anticholinergic, and chemopreventive activities; moreover, amarogentin has been proven for its anti-leishmanial activity. Antileishmanial studies have been conducted in vitro and in animal models, with encouraging results, but no human clinical trials have been published for this indication.

5.8 Neuroprotective and CNS Activity

The bioactivities of Swertia plants include CNS-depressant activity. Swertiamarin's metabolic conversion to gentianine by the gut microbiome is relevant here, as gentianine is a pyridine alkaloid with documented CNS activity. Swertiamarin has also been reported to have antidepressant effects. These findings are from preclinical models; no well-powered human trials have been conducted.

5.9 Anti-hepatitis B Virus (Anti-HBV) Activity

Recently, S. chirayita extracts showed anti-hepatitis B virus (anti-HBV) activities. This preclinical finding corroborates the traditional use of chirayita in Ayurvedic formulations for viral hepatitis (e.g., the formulation "Kabdeen" used for treating viral hepatitis). Evidence remains in vitro, and no clinical trial data have been published to validate efficacy in HBV-infected humans.

6. Body Systems and Health Areas Associated with Swertia

• Hepatobiliary System: Hepatoprotection, anti-HBV activity, treatment of jaundice and hepatitis, stimulation of bile secretion
• Endocrine / Metabolic System: Blood glucose regulation, insulin secretion stimulation (via swerchirin), antidiabetic applications
• Gastrointestinal System: Bitter tonic for appetite stimulation, gastric motility modulation, gastroprotection (anti-ulcer), anthelmintic, antidiarrheal
• Immune and Infectious Disease: Antimalarial, antibacterial, antifungal, antiviral (anti-HBV), antileishmanial
• Cardiovascular System: Hypolipidemic (reduction of LDL and triglycerides), anti-atherosclerotic, antihypertensive (traditional use)
• Central Nervous System: CNS-depressant, antidepressant, neuroprotective (preclinical)
• Integumentary System: Skin disease treatment (traditional); anticancer potential relevant to skin carcinogenesis (preclinical)
• Musculoskeletal System: Anti-arthritic, anti-osteoclastogenic, analgesic (all preclinical)

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported specifically as used in cited studies or described in traditional practice in the reviewed literature. These are not prescriptive recommendations.

• S. chirayita extract at doses of 100–200 mg/kg was administered orally in Swiss albino mice in a paracetamol-induced hepatotoxicity study, showing significant dose-dependent hepatoprotection.
• The methanol extract of the whole plant was found active at a dose of 100 mg/kg i.p. in a galactosamine/paracetamol hepatotoxicity rat model; the chloroform-soluble fraction showed activity at 25 mg/kg i.p.
• In cell-culture hepatotoxicity studies, primary rat hepatocyte cultures were exposed to plant extracts at 100 µg/mL in culture medium.
• Methanolic extract was identified with glucuronidase inhibition activity with an IC₅₀ value of 162.84 ± 3.72 µg/ml for swerchirin along with mangiferin.
• In commercial Ayurvedic formulations, herbal formulations containing S. chirayita extract include Ayush-64 and Diabecon at different concentrations, with their specific dosing dictated by the formulation monographs of the respective manufacturers.

Human clinical dosing data for Swertia extracts or isolated compounds as standalone interventions are not available from the peer-reviewed sources reviewed here, reflecting the absence of published controlled human clinical trials with rigorously defined dosing protocols.

8. Safety Considerations and Known Interactions

8.1 General Safety Profile

So far no toxicity or serious side effects have been reported during various applications of Swertia chirayita plant extract, although further extensive toxicological research is necessary. There is a lack of adequate information on the safety evaluation of the plant.

Despite its extensive historical usage in traditional herbal medicine, there is currently a scarcity of scientific evidence on the safety of S. chirayita. The absence of reported serious adverse events in traditional use contexts is noted, but formal toxicological studies — including chronic toxicity, reproductive toxicity, or genotoxicity in validated animal models — are limited in number.

8.2 Elemental Composition and Toxic Elements

Mg, Ca, K, Fe, Sr, Cr, and Na were verified as necessary elements in S. chirayita by optical emission investigations, while Al, Ti, Si, Ba, Mn, and Li were non-essential. The concentration of Ca and Fe is higher than other detected elements. All the toxic elements are found to be within the safe limit in compositional analyses of authenticated plant material.

8.3 Pharmacokinetic Limitations and Bioavailability

Pharmacokinetic studies reveal that swertiamarin exhibits rapid absorption but demonstrates low oral bioavailability due to the first-pass effect. A 2025 comprehensive review further noted that the low oral bioavailability, short half-life, and rapid metabolism properties of swertiamarin are important challenges to therapeutic efficacy. These pharmacokinetic limitations mean that the dosages that produce effects in animal models may not translate directly to equivalent human exposures.

8.4 Adulteration: A Major Safety Concern

The increasing national and international demand for Swertia chirayita has led to unscrupulous collection from the wild and adulteration of supplies. The plant available in the market many a times is adulterated and substituted by close relatives of chirata. Due to its high demand and scarcity, several other species of Swertia — including S. alata, S. angustifolia, S. cordata, S. purpurascens, and S. paniculata — are being used as substitutes or adulterants for S. chirayita in India, Japan, China, Pakistan, and other Asian countries. Due to its high demand and scarcity, S. chirayita is being frequently adulterated with other species of Swertia which are more readily available. Presently almost all the similar-looking species of Swertia are marketed as "chirayita" without any rationale, which is affecting the potency of the drug. This adulteration represents a meaningful safety and efficacy concern for consumers of commercial preparations.

8.5 Drug Interactions

Formal human pharmacokinetic drug–drug interaction studies for Swertia preparations are not available in the reviewed literature. However, based on the identified mechanisms of action, potential theoretical interactions are noted in the research literature: the antidiabetic activity (via insulin secretion and blood glucose reduction) may potentiate the effects of hypoglycemic medications, and the anti-inflammatory effects may interact with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. These interactions remain theoretical in the absence of clinical data.

8.6 Conservation Status and Supply-Chain Concerns

S. chirayita has been declared an extremely endangered species due to over-exploitation of its herbal raw material as whole plants. The increasing high usage of Swertia chirayita, mostly the underground tissues, as well as the illegal overharvesting combined with habitat destruction, resulted in a drastic reduction of its populations and has brought this plant to the verge of extinction. The endangered status of the primary botanical source means that sustainable sourcing and authentication of commercial products are critical considerations. Tissue culture approaches for ex situ conservation and production have been investigated as part of ongoing efforts to meet demand without further depleting wild populations.

8.7 Need for Clinical Trials

The pharmacological activities and therapeutic potential of swertiamarin have been extensively investigated. However, more advanced studies are required including clinical trials and studies on the bioavailability, permeability, and administration of safe doses to offer swertiamarin as a novel candidate for future drug development. This assessment reflects the state of evidence for Swertia broadly: a strong preclinical evidence base with promising pharmacological activity, but a persistent gap in well-designed human clinical trial data.

References

• Li J, Zhao YL, Huang HY, Wang YZ. Phytochemistry and Pharmacological Activities of the Genus Swertia (Gentianaceae): A Review. Am J Chin Med. 2017;45(4):667–736. PubMed PMID: 28490237
• Guo S et al. Swertia L.: A comprehensive review of its genetic relationship, chemical compositions, pharmacological effects, toxicities, and applications. Phytother Res. 2023. PubMed PMID: 37143212
• Swati K, Bhatt V, Sendri N, Bhatt P, Bhandari P. Swertia chirayita: A comprehensive review on traditional uses, phytochemistry, quality assessment and pharmacology. J Ethnopharmacol. 2023 Jan 10;300:115714. PubMed PMID: 36113678
• Ballabh B, Chaurasia OP. A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant. Frontiers in Pharmacology. 2015;6:308. PMC4709473
• Dey P, Singh J et al. Utilization of Swertia chirayita Plant Extracts for Management of Diabetes and Associated Disorders: Present Status, Future Prospects and Limitations. Nat Prod Bioprospect. 2020 Dec;10(6):431–443. PMC7648839
• Muhamad Fadzil NS, Sekar M et al. Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin – A Promising Natural Lead for New Drug Discovery and Development. Drug Des Devel Ther. 2021. PMC8233004
• Muhamad Fadzil NS et al. Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin. PubMed PMID: 34188450
• Yang HX, Hu YY, Liang R, Zheng H, Zhang X. Progress in Pharmacokinetics, Pharmacological Effects, and Molecular Mechanisms of Swertiamarin: A Comprehensive Review. Cells. 2025;14(15):1173. PMC12346835
• Nagalekshmi R, Menon A, Chandrasekharan DK, Nair CK. Hepatoprotective activity of Andrographis paniculata and Swertia chirayita. Food Chem Toxicol. 2011 Dec;49(12):3367–73. PubMed PMID: 21983487
• Karan M, Vasisht K, Handa SS. Antihepatotoxic activity of Swertia chirata on paracetamol and galactosamine induced hepatotoxicity in rats. Phytother Res. 1999. PubMed PMID: 10190179
• Karan M, Vasisht K, Handa SS. Antihepatotoxic activity of Swertia chirata on carbon tetrachloride induced hepatotoxicity in rats. PubMed PMID: 10189946
• Medda S et al. Screening of various Swertia species extracts in primary monolayer cultures of rat hepatocytes against carbon tetrachloride- and paracetamol-induced toxicity. PubMed PMID: 11297858
• Patel K et al. Amarogentin as Topical Anticancer and Anti-Infective Potential: Scope of Lipid Based Vesicular in its Effective Delivery. Recent Pat Antiinfect Drug Discov. 2019;14(1):7–15. PubMed PMID: 30210007
• Systematic review of the protective role of swertiamarin in cardiac and metabolic diseases. ScienceDirect (Phytomedicine/related journal), 2016.
• Swertia chirayita biosynthetic pathways — detection of intermediates through HRMS. PubMed PMID: 25622657
• Chi X, Zhang F, Gao Q, Xing R, Chen S. A Review on the Ethnomedicinal Usage, Phytochemistry, and Pharmacological Properties of Gentianeae (Gentianaceae) in Tibetan Medicine. Plants (Basel). 2021;10(11):2383. PMC8620629
• Xu X et al. Comparative and phylogenetic analyses of Swertia L. (Gentianaceae) medicinal plants based on complete chloroplast genomes. PMC8679245
• Biochemical characterization of bioinspired nanosuspensions from Swertia chirayita extract. PMC10852254
• Optimizing nutrient media conditions for continuous production of shoot biomass enriched in amarogentin and mangiferin of Swertia chirayita. PMC9423889
• ScienceDirect Topics: Swertia — overview, ethnopharmacology, phytochemistry, and pharmacology.
• Ethanopharmacology, phytochemistry and pharmacology of medicinally potent genus Swertia: An update. South African Journal of Botany. 2019. ScienceDirect.
• Compositional analysis of Swertia chirayita medicinal plant using laser-induced breakdown spectroscopy and ICP-MS. PMC11414975